Estudio de cohorte de pacientes con neoplasias malignas atendidos por infección respiratoria aguda (IRA) en el Instituto Nacional de Cancerología (INC) durante la pandemia por COVID-19 mayo 2020- agosto 2021

dc.contributor.advisorCuervo Maldonado, Sonia Isabelspa
dc.contributor.advisorCarolina, Wiesner Ceballosspa
dc.contributor.advisorGómez Rincón, Julio Césarspa
dc.contributor.advisorSánchez, Ricardospa
dc.contributor.advisorMontañez Ayala, Anita Maríaspa
dc.contributor.advisorGarcía Guzmán, Katherinespa
dc.contributor.authorRojas Perdomo, Juan Davidspa
dc.contributor.researchgroupGreicah Grupo en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicasspa
dc.coverage.temporal2020-2021
dc.date.accessioned2022-02-10T15:24:48Z
dc.date.available2022-02-10T15:24:48Z
dc.date.issued2021-12-24
dc.descriptionilustraciones, gráficas, tablasspa
dc.description.abstractEstudio de Cohorte de pacientes con neoplasias malignas atendidos por infección respiratoria aguda (IRA) en el Instituto Nacional de Cancerología (INC) durante la pandemia por COVID-19 mayo 2020- agosto 2021 Introducción: Los pacientes con neoplasias malignas son una población de alto riesgo. Se describe una caracterización exhaustiva de pacientes con cáncer e infección respiratoria aguda (IRA) durante la pandemia por COVID-19 y se analizan factores de riesgo para ventilación mecánica invasiva y muerte en esta población. Métodos: Estudio de cohorte ambispectivo, de 644 pacientes con IRA y cáncer desde Mayo de 2020 a Agosto de 2021. Se realizó seguimiento a 30 días del egreso hospitalario. Características clínicas, paraclínicas, imagenológicas e historia de cáncer fueron comparados entre sobrevivientes y no sobrevivientes, y entre positivos y negativos para COVID-19. Factores de riesgo para ventilación mecánica invasiva y muerte fueron identificados usando modelos de regresión logística univariable y multivariables. Resultados: 644 pacientes con IRA y neoplasias malignas fueron abarcados (mediana edad 60 años (IQR 23);48.5% mujeres). 421 (65.3%) tenían tumores sólidos y 219 (34%) hematológicos. El más frecuente fue el cáncer de mama (67/421) seguido por colorrectal (46/421) y próstata (42/421) (15%, 10% y 9% respectivamente). 161 (25%) recibieron quimioterapia en los 30 días previos al diagnóstico de IRA. 30.4% de los pacientes ingresó a UCI y 93.8% requirió ventilación mecánica invasiva. La mortalidad global a 30 días fue del 50.4%, 53.7% en el grupo de infección por COVID 19. 60.17% directamente relacionado a IRA y 31.23% asociado a neoplasia maligna de base. Conclusiones: Los pacientes con neoplasias malignas e IRA quienes fueron admitidos al hospital tiene una alta tasa de mortalidad no relacionado a la identificación de SARS-CoV2 como agente causal. (Texto tomado de la fuente).spa
dc.description.abstractStudy cohort of patients with malignant neoplasms treated for Acute Respiratory Infection in the Instituto Nacional de Cancerologia (INC) during the COVID-19 pandemic from May 2020 to August 2021 Introduction: Patients with malignant neoplasms are a high-risk population. A comprehensive characterization of cancer patients with acute respiratory infection (ARI) during the COVID-19 pandemic is described and risk factors for invasive mechanical ventilation and death in this population are analyzed. Methods: Ambispective cohort study of 644 patients with ARI and cancer, from May 2020 to August 2021. Follow-up was carried out 30 days after hospital discharge. Clinical, paraclinical, imaging characteristics and history of cancer were compared between survivors and non-survivors, and between positive and negative COVID-19 cases. Risk factors for invasive mechanical ventilation and death were identified using univariate and multivariate logistic regression models. Results: 644 patients with ARI and malignant neoplasms were included (median age: 60 years (IQR 23); 48.5% women). 421 (65.3%) had solid tumors and 219 (34%) hematological ones. The most frequent was breast cancer (67/421) followed by colorectal (46/421) and prostate (42/421) (15%, 10% and 9% respectively). 161 (25%) received chemotherapy in the 30 days prior to ARI diagnosis. 30.4% of the patients were admitted to the ICU and 93.8% required invasive mechanical ventilation. Overall 30-day mortality was 50.4%, 53.7% in the COVID-19 infection group. 60.17% directly related to ARI and 31.23% associated with the underlying malignancy. Conclusions: Patients with malignant neoplasms and ARI admitted to the hospital had a high mortality rate not related to the identification of SARS-CoV2 as a causal agent.eng
dc.description.degreelevelEspecialidades Médicasspa
dc.description.degreenameEspecialista en Medicina Internaspa
dc.description.methodsEstudio observacional, analítico, de cohorte ambispectivo.spa
dc.description.notesIncluye anexosspa
dc.description.researchareaEpidemiología descriptiva y sistemas de vigilancia del cáncerspa
dc.format.extentxvii, 59 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/80931
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Medicina Internaspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Internaspa
dc.relation.indexedBiremespa
dc.relation.referencesWang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061–9.spa
dc.relation.referencesChen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.spa
dc.relation.referencesRodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020:101623.spa
dc.relation.referencesSaavedra Trujillo CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infectio 2020;24:1.spa
dc.relation.referencesYu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020.spa
dc.relation.referencesGuan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020:NEJMoa2002032.spa
dc.relation.referencesMacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1117 Public Health and Health Services. BMC Infect Dis 2018;18:637.spa
dc.relation.referencesKlein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respi Viruses 2016;10:394–403.spa
dc.relation.referencesAnexo versión 9. Instituto Nacional de Salud. Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19) 2020;Versión 9.spa
dc.relation.referencesKamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009;10:589–97.spa
dc.relation.referencesLiang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335–7.spa
dc.relation.referencesZhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.spa
dc.relation.referencesMinisterio de Salud y protección social C, Instituto Nacional de Cancerología C. Plan Decenal para el Control del Cáncer en Colombia, 2012 – 2021 2012.spa
dc.relation.referencesMorens DM, Fauci AS. The 1918 Influenza Pandemic: Insights for the 21st Century. J Infect Dis 2007;195:1018–28.spa
dc.relation.referencesDauer CC, Serfling RE. Mortality from Influenza. Am Rev Respir Dis 1961;83:15–28.spa
dc.relation.referencesAlling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am J Epidemiol 1981;113:30–43.spa
dc.relation.referencesMorens DM, Taubenberger JK, Fauci AS. Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness. J Infect Dis 2008;198:962–70.spa
dc.relation.referencesBooth CM. Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. JAMA 2003;289:2801.spa
dc.relation.referencesMartín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al. Community-acquired respiratory coinfection in critically III patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011;139:555–62.spa
dc.relation.referencesLee EH, Wu C, Lee EU, Stoute A, Hanson H, Cook HA, et al. Fatalities Associated with the 2009 H1N1 Influenza A Virus in New York City. Clin Infect Dis 2010;50:1498–504.spa
dc.relation.referencesWu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. Emerg Infect Dis 2020;26.spa
dc.relation.referencesTouzard-Romo F, Tapé C, Lonks JR. Co-infection with SARS-CoV-2 and Human Metapneumovirus. R I Med J (2013) 2020;103:75–6.spa
dc.relation.referencesVilar-Compte D, Shah DP, Vanichanan J, Cornejo-Juarez P, Garcia-Horton A, Volkow P, et al. Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. J Med Virol 2018;90:50–60.spa
dc.relation.referencesChoi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011;117:5050–6.spa
dc.relation.referencesTai Y, Lee TC, Chang HL, Chen KT. Epidemiology and outcomes of hospitalization of influenza in the cancer population in Taiwan. J Cancer Res Clin Oncol 2009;135:1061–6.spa
dc.relation.referencesMikulska M, Del Bono V, Gandolfo N, Dini S, Dominietto A, Di Grazia C, et al. Epidemiology of viral respiratory tract infections in an outpatient haematology facility. Ann Hematol 2014;93:669–76.spa
dc.relation.referencesRedelman-Sidi G, Sepkowitz KA, Huang CK, Park S, Stiles J, Eagan J, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect 2010;60:257–63.spa
dc.relation.referencesSaad M, Hayajneh W, Mubarak S, Yousef I, Awad H, Elbjeirami W, et al. Clinical presentations and outcomes of influenza infection among hematology/oncology patients from a single cancer center: Pandemic and post-pandemic seasons. Scand J Infect Dis 2014;46:770–8.spa
dc.relation.referencesFalsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014;209:1873–81.spa
dc.relation.referencesLivingston E, Bucher K, Rekito A. Coronavirus Disease 2019 and Influenza 2019-2020. JAMA 2020;323:1122.spa
dc.relation.referencesWeng TC, Chiu HYR, Chen SY, Shih FY, King CC, Fang CC. National retrospective cohort study to identify age-specific fatality risks of comorbidities 012019;9:e025276.spa
dc.relation.referencesDhanoa A, Fang NC, Hassan SS, Kaniappan P, Rajasekaram G. Epidemiology and clinical characteristics of hospitalized patients with pandemic influenza A (H1N1) 2009 infections: The effects of bacterial coinfection. Virol J 2011;8:501.spa
dc.relation.referencesNM K, TK C, DP S, Y S, SM R, DR R, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England) 2020;395:1907–18.spa
dc.relation.referencesGroup TRC. Dexamethasone in Hospitalized Patients with Covid-19. Https://DoiOrg/101056/NEJMoa2021436 2020;384:693–704.spa
dc.relation.referencesDesai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, et al. Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer 2021;127:1459–68.spa
dc.relation.referencesYang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:904–13.spa
dc.relation.referencesPinato DJ, Lee AJX, Biello F, Seguí E, Aguilar-Company J, Carbó A, et al. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers 2020, Vol 12, Page 1841 2020;12:1841.spa
dc.relation.referencesJ J, MB F, M L, AJ S, B W, V N, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol 2020;38:3538–46.spa
dc.relation.referencesPinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, et al. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discov 2020;10:1465–74.spa
dc.relation.referencesNational Institute for Health and Care Excellence (NICE). COVID-19 Rapid Guideline: Delivery of SystemicAnticancer Treatments NICE Guidelinespa
dc.relation.referencesRivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, et al. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov 2020;10:1514–27.spa
dc.relation.referencesDettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U, et al. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. J Immunother Cancer 2021;9:2277.spa
dc.relation.referencesWu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.spa
dc.relation.referencesPalmieri C, Turtle L, Docherty A, Harrison E, Drake T, Greenhalf B, et al. 1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium. Ann Oncol 2020;31:S992.spa
dc.relation.referencesLi A, Kuderer NM, Hsu CY, Shyr Y, Warner JL, Shah DP, et al. The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. J Thromb Haemost 2021;19:2522–32.spa
dc.relation.referencesS R, JS H, M N, JM C, T M, KW D, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020;323:2052–9.spa
dc.relation.referencesPetrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369.spa
dc.relation.referencesAV O, R B, W M, I T, P R, S A, et al. Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study. Oncologist 2021;26:e1761–73.spa
dc.relation.referencesKuderer NM, Wulff-Burchfield E, Rubinstein SM, Grivas P, Warner JL. Cancer and COVID-19 – Authors’ reply. Lancet 2020;396:1067–8.spa
dc.relation.referencesMarron JM, Joffe S, Jagsi R, Spence RA, Hlubocky FJ. Ethics and Resource Scarcity: ASCO Recommendations for the Oncology Community During the COVID-19 Pandemic. J Clin Oncol 2020;38:2201–5spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.subject.ddc610 - Medicina y saludspa
dc.subject.decsHealth Services Researcheng
dc.subject.decsInvestigación sobre Servicios de Saludspa
dc.subject.decsNeoplasiasspa
dc.subject.decsNeoplasmseng
dc.subject.decsRespiratory Tract Diseaseseng
dc.subject.decsEnfermedades Respiratoriasspa
dc.subject.proposalCOVID-19spa
dc.subject.proposalInfección respiratoria agudaspa
dc.subject.proposalSíndrome de distrés respiratoriospa
dc.subject.proposalCOVID-19eng
dc.subject.proposalMalignant Neoplasmseng
dc.subject.proposalCohort studieseng
dc.subject.proposalNeumoníaspa
dc.subject.proposalChoque sépticospa
dc.subject.proposalNeoplasias malignasspa
dc.subject.proposalEstudio cohortespa
dc.subject.proposalPneumoniaeng
dc.subject.proposalAcute respiratory infectioneng
dc.subject.proposalRespiratory distress syndromeeng
dc.subject.proposalSeptic shockeng
dc.titleEstudio de cohorte de pacientes con neoplasias malignas atendidos por infección respiratoria aguda (IRA) en el Instituto Nacional de Cancerología (INC) durante la pandemia por COVID-19 mayo 2020- agosto 2021spa
dc.title.translatedStudy cohort of patients with malignant neoplasms treated for Acute Respiratory Infection in the Instituto Nacional de Cancerologia (INC) during the COVID-19 pandemic from May 2020 to August 2021eng
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentEstudiantesspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
dcterms.audience.professionaldevelopmentResponsables políticosspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.fundernameInstituto Nacional de Cancerologíaspa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1110564509.2021.pdf.pdf
Tamaño:
858.28 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Especialidad en Medicina interna

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
3.98 KB
Formato:
Item-specific license agreed upon to submission
Descripción: